Novo Nordisk A/S

New data reveal why physicians and people with type 2 diabetes uncontrolled on basal insulin are reluctant to intensify insulin therapy

Vancouver, Canada (ots/PRNewswire) - This material is intended for global medical media only.

This material is not approved for Canadian journalists or Canadian audiences.

For journalistic assessment and preparation before publication.

Results from the Perceptions of Control (POC) study showed that people with type 2 diabetes uncontrolled on basal insulin were reluctant to intensify insulin therapy due to concerns such as medication side effects, perceptions of getting sicker and not wanting to add more injections. Physicians' concerns around insulin intensification included a lack of patient agreement to intensify insulin therapy, hypoglycaemia and patients' cognitive status.[1] Findings from the Perceptions of Control study which evaluated the perceptions of diabetes control amongst patients and physicians were presented today at the World Diabetes Congress of the International Diabetes Federation (IDF).

"A better understanding of how patients and physicians make decisions around insulin intensification could significantly improve communication during consultations and help people with type 2 diabetes, uncontrolled on basal insulin, to intensify treatment when needed," said Meryl Brod, PhD, lead investigator of the POC study. "Addressing patient concerns with additional information and treatment options may lead to an increased number of patients agreeing to change their treatment to get into better control."

The POC study results showed that people with type 2 diabetes uncontrolled on basal insulin were apprehensive to intensify therapy and initiate basal-bolus insulin despite their physician's recommendation due to factors such as fear of weight gain caused by the medication (45%), feeling they were getting sicker (44%), fear of hypoglycaemia (low blood sugar) (41%) and not wanting to add more injections (41%).[1] In total, over half (57%) were only somewhat or not at all willing (39% somewhat / a little willing, 18% not at all willing) to add one additional daily injection of bolus insulin to help control their type 2 diabetes and 37% were concerned that the regimen would be too complicated.[1]

Physician study participants reported that the primary reason they were reluctant to intensify insulin therapy for people with type 2 diabetes uncontrolled on basal insulin was due to thinking their patients would not agree (62%).[1] Physicians were also reluctant to intensify therapy due to concerns around hypoglycaemia (46%), especially if it was particularly dangerous in a patient's workplace (54%).[1] Physicians were also concerned about recommending intensification if a patient had a mental illness or altered mental status (48%),[1] poor cognitive skills (46%) and concerns of patient compliance (41%).[1]

About the Perceptions of Control (POC) Study

The POC study was based on information collected from a web survey of 300 physicians and 1,012 adults with type 2 diabetes uncontrolled on basal insulin (physician-confirmed HbA1c> 8% (64 mmol/mol)) from the UK (n=100 physicians and 620 patients), Sweden (n=100 physicians and 240 patients) and Switzerland (n=100 physicians and 152 patients). Information was also collected from a control group of 295 adults with type 2 diabetes controlled on basal insulin (physician-confirmed HbA1c <7.5% (59 mmol/mol) from the UK. In total, data were collected from 1,607 patients and physicians for analysis.[1]-[3] The purpose of the study was to explore how physicians and people with type 2 diabetes define control, identify obstacles to achieving control,[2],[3] perceive the impact of uncontrolled type 2 diabetes on daily life[2],[3] and reluctance to intensify insulin therapy.[1]

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com (http://www.novonordisk.com/), Facebook (http://www.facebook.com/novonordisk), Twitter (http://www.twitter.com/novonordisk), LinkedIn (http://www.linkedin.com/company/novo-nordisk), YouTube (http://www.Youtube.com/novonordisk)

Further information

Media:  Katrine Sperling             +45 4442 6718    
krsp@novonordisk.com 
Åsa Josefsson                +45 3079 7708 aajf@novonordisk.com 
Investors:  Peter Hugreffe Ankersen  +45 3075 9085    
phak@novonordisk.com 
Daniel Bohsen  +45 3079 6376  dabo@novonordisk.com 
Melanie Raouzeos  +45 3075 3479  mrz@novonordisk.com 
Kasper Veje                  +45 3079 8519 kpvj@novonordisk.com 
Frank Daniel Mersebach (US)  +1 609 235 8567  fdni@novonordisk.com 

_______________________

References

1. Brod M, Pfeiffer KM, Barnett AH, et al. Patient/physicians inertia
   in insulin intensification for patients with uncontrolled type 2 
   diabetes using basal insulin. Poster presentation (1081-P) at the 
   International Diabetes Federation (IDF) World Diabetes Congress, 1
   December 2015.
2. Brod M, Pfeiffer KM, Barnett AH, et al. Perceptions of control 
   among type 2 diabetes patients treated with basal insulin. Poster 
   presentation (0742-P) at the International Diabetes Federation 
   (IDF) World Diabetes Congress, 1 December 2015.
3. Brod M, Pfeiffer KM, Barnett AH, et al. Perceptions of diabetes 
   control among physicians and patients with uncontrolled type 2 
   diabetes using basal insulin. Poster presentation (0741-P) at the 
   International Diabetes Federation (IDF) World Diabetes Congress, 1
   December 2015. 

 

Weitere Meldungen: Novo Nordisk A/S

Das könnte Sie auch interessieren: